|1.||Hodgson, Robert A: 4 articles (04/2014 - 10/2008)|
|2.||Parker, Eric M: 3 articles (04/2014 - 10/2008)|
|3.||Hunter, John C: 3 articles (03/2014 - 10/2008)|
|4.||Bleickardt, Carina J: 2 articles (04/2014 - 03/2014)|
|5.||Varty, Geoffrey B: 2 articles (07/2009 - 10/2008)|
|6.||Mullins, Deborra E: 1 article (04/2014)|
|7.||Innocent, Nathalie: 1 article (04/2014)|
|8.||Hodge, Lisa M: 1 article (04/2014)|
|9.||Jayaraman, Srinivasan: 1 article (04/2014)|
|10.||Browne, Susan E: 1 article (04/2014)|
07/01/2009 - "These studies demonstrate that preladenant and SCH 412348 are potent and selective A(2A) receptor antagonists and provide further evidence of the potential therapeutic benefits of A(2A) receptor inhibition in PD (with reduced risk of dyskinesias) and depression (one of the primary nonmotor symptoms of PD)."
09/01/2013 - "When delivered to animals previously sensitized with L-dopa (6 mg/kg), SCH 412348, vipadenant, caffeine or istradefylline treatment produced no dyskinesias. "
|2.||Parkinson Disease (Parkinson's Disease)
04/05/2014 - "Moreover, SCH 412348 retained its efficacy in the mice as motor impairment progressed (12-22 weeks of age), demonstrating that the compound was efficacious in mild to severe Parkinson's disease-like impairment in the mice. "
04/01/2014 - "MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348."
|3.||Movement Disorders (Movement Disorder)
04/05/2014 - "SCH 412348 is a potent and selective adenosine A2A receptor antagonist that shows efficacy in rodent and primate models of movement disorders. "
07/01/2009 - "Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression."
|5.||Psychomotor Agitation (Akathisia)
|2.||Caffeine (No Doz)
|3.||Adenosine A2A Receptor (Adenosine A2A Receptors)
|4.||Levodopa (L Dopa)
|8.||4- (4- (4- chlorophenyl)- 4- hydroxy- 1- piperidinyl)- 1- (4- fluorophenyl)- 1- butanol